The Chronic Norovirus Enteritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Norovirus Enteritis: An Overview
Norovirus also called as Winter Vomiting bug is a small virus that contains Ribonucleic acid (RNA) and is surrounded by a protein coating. As of now, there are 25 strains of norovirus that affect humans. The RNA genome in noroviruses easily mutates to produce new norovirus types swiftly.
Norovirus is a highly contagious stomach and intestinal virus. It is easily transmitted by coming into contact with an infected individual, either directly or indirectly. In close quarters, such as hospitals, schools, and daycare centers, it can spread swiftly by coming in contact with a patient affected with norovirus who may breathe out small particles of the virus that can be then inhaled, touching any contaminated surfaces or objects, as the virus can survive outside the body for several days, eating contaminated food, which can happen if an infected person doesn’t wash their hands before preparing or handling food.
Chronic Norovirus Enteritis Market Key Facts
-
According to the Centers for Disease Control and Prevention (n.d), norovirus causes gastroenteritis in ~19–21 million people per year in the US. The virus is also responsible for 56,000–71,000 annual hospitalizations and 570–800 deaths in the US every year.
-
As per the study by Shah and Hall (2018), titled “Norovirus Illnesses in Children and Adolescents”, it was reported that Asymptomatic norovirus infection, identified through stool shedding of norovirus in patients without gastroenteritis, was found in 3% to 10% of children and adults.
-
In a study conducted by Belliot et al. (2014), it was reported that in Europe, 10% of norovirus outbreaks are reported by investigators to be spread primarily by foodborne transmission, as compared with 26% in the US. However, if the mode of transmission is assigned to the outbreak based on genotype profiles and other outbreak characteristics, the foodborne percentage rises to 20%.
Chronic Norovirus Enteritis Market
Chronic Norovirus Enteritis market size is anticipated to increase during the forecast period owing to the increase in the prevalence of the disease, along with collaborative efforts of pharmaceutical companies, academia, and others.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Norovirus Enteritis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Chronic Norovirus Enteritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- Chronic Norovirus Enteritis Therapeutics Market
Chronic Norovirus Enteritis Epidemiology
The epidemiology section covers insights about the historical and current Chronic Norovirus Enteritis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Norovirus Enteritis Epidemiology Segmentation
-
Total prevalent cases of Chronic Norovirus Enteritis
-
Total diagnosed prevalent cases of Chronic Norovirus Enteritis
-
Treated cases of Chronic Norovirus Enteritis
-
Age-specific diagnosed prevalent cases of Chronic Norovirus Enteritis
Chronic Norovirus Enteritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Norovirus Enteritis market or expected to get launched in the market during the study period. The analysis covers Chronic Norovirus Enteritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Norovirus Enteritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Chronic Norovirus Enteritis Therapeutics Analysis
The emerging landscape of Chronic Norovirus Enteritis is not very robust. Not many companies have indulged themselves in developing a novel treatment option for this condition
Some of the key companies in the Chronic Norovirus Enteritis Market include:
-
Lumen Bioscience
-
Cocrystal pharma
-
Prosit Sole Biotechnology
And others
Chronic Norovirus Enteritis Therapies –
-
PSP001 – PSP001 is being developed by Prosit Sole Biotechnology is a novel, phase I long-acting, and potent interferon lambda chimera injection. PEGinterferon λ1-λ3 Chimera is the active pharmaceutical ingredient involved in PSP001. The unique receptor IFNλR1 is particularly abundant at the barrier surfaces, such as the respiratory tracts, the gastrointestinal tracts, and the liver.
-
VXA-G1.1-NN – Vaxart is developing the VXA-G1.1-NN vaccine and it is currently in Phase I/II of development. Takeda is also developing its Norovirus vaccine and is currently in Phase II of development. Aside from these, vaccine clinical studies are being conducted by a few additional companies.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/chronic-norovirus-enteritis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Norovirus Enteritis Competitive Intelligence Analysis
4. Chronic Norovirus Enteritis Market Overview at a Glance
5. Chronic Norovirus Enteritis Disease Background and Overview
6. Chronic Norovirus Enteritis Patient Journey
7. Chronic Norovirus Enteritis Epidemiology and Patient Population
8. Chronic Norovirus Enteritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Norovirus Enteritis Unmet Needs
10. Key Endpoints of Chronic Norovirus Enteritis Treatment
11. Chronic Norovirus Enteritis Marketed Products
12. Chronic Norovirus Enteritis Emerging Therapies
13. Chronic Norovirus Enteritis Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Norovirus Enteritis Market Outlook (7 major markets)
16. Chronic Norovirus Enteritis Access and Reimbursement Overview
17. KOL Views on the Chronic Norovirus Enteritis Market.
18. Chronic Norovirus Enteritis Market Drivers
19. Chronic Norovirus Enteritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/chronic-norovirus-enteritis-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/